학술논문
High-Sensitivity C-Reactive Protein is a Prognostic Biomarker of Six-Month Disability after Traumatic Brain Injury: Results from the TRACK-TBI Study
Document Type
article
Author
Xu, Linda B; Yue, John K; Korley, Frederick; Puccio, Ava M; Yuh, Esther L; Sun, Xiaoying; Rabinowitz, Miri; Vassar, Mary J; Taylor, Sabrina R; Winkler, Ethan A; Puffer, Ross C; Deng, Hansen; McCrea, Michael; Stein, Murray B; Robertson, Claudia S; Levin, Harvey S; Dikmen, Sureyya; Temkin, Nancy R; Giacino, Joseph T; Mukherjee, Pratik; Wang, Kevin KW; Okonkwo, David O; Markowitz, Amy J; Jain, Sonia; Manley, Geoffrey T; Diaz-Arrastia, Ramon; Adeoye, Opeolu; Badjatia, Neeraj; Boase, Kim; Bodien, Yelena; Bullock, M Ross; Chesnut, Randall; Corrigan, John D; Crawford, Karen; Duhaime, Ann-Christine; Ellenbogen, Richard; Feeser, V Ramana; Ferguson, Adam R; Foreman, Brandon; Gardner, Raquel; Gaudette, Etienne; Goldman, Dana; Gonzalez, Luis; Gopinath, Shankar; Gullapalli, Rao; Hemphill, J Claude; Hotz, Gillian; Kramer, Joel; Kreitzer, Natalie; Lindsell, Chris; Machamer, Joan; Madden, Christopher; Martin, Alastair; McAllister, Thomas; Merchant, Randall; Nelson, Lindsay; Ngwenya, Laura B; Noel, Florence; Okonkwo, David; Palacios, Eva; Perl, Daniel; Rosand, Jonathan; Sander, Angelle; Satris, Gabriella; Schnyer, David; Seabury, Seth; Toga, Arthur; Adeoye, Alex VaOpeolu
Source
Journal of Neurotrauma. 38(7)
Subject
Language
Abstract
Systemic inflammation impacts outcome after traumatic brain injury (TBI), but most TBI biomarker studies have focused on brain-specific proteins. C-reactive protein (CRP) is a widely used biomarker of inflammation with potential as a prognostic biomarker after TBI. The Transforming Research and Clinical Knowledge in Traumatic Brain Injury (TRACK-TBI) study prospectively enrolled TBI patients within 24 h of injury, as well as orthopedic injury and uninjured controls; biospecimens were collected at enrollment. A subset of hospitalized participants had blood collected on day 3, day 5, and 2 weeks. High-sensitivity CRP (hsCRP) and glial fibrillary acidic protein (GFAP) were measured. Receiver operating characteristic analysis was used to evaluate the prognostic ability of hsCRP for 6-month outcome, using the Glasgow Outcome Scale-Extended (GOSE). We included 1206 TBI subjects, 122 orthopedic trauma controls (OTCs), and 209 healthy controls (HCs). Longitudinal biomarker sampling was performed in 254 hospitalized TBI subjects and 19 OTCs. hsCRP rose between days 1 and 5 for TBI and OTC subjects, and fell by 2 weeks, but remained elevated compared with HCs (p